Cramer's 'Mad Money' Recap: Gone Bottom-Fishin'

In 1990, Citigroup worked, but right now Goldman Sachs (GS - Cramer's Take - Stockpickr), which he also owns for his charitable trust, is the best of the financials and should be bought, Cramer said. People should also consider getting into Apple (AAPL - Cramer's Take - Stockpickr), Research In Motion (RIMM - Cramer's Take - Stockpickr) and Google (GOOG - Cramer's Take - Stockpickr).

For the short term, Intuitive Surgical (ISRG - Cramer's Take - Stockpickr) and Amazon (AMZN - Cramer's Take - Stockpickr) work, he added.

Cramer also said he sees a hidden trend in natural gas. There his favorite plays are Halliburton (HAL - Cramer's Take - Stockpickr) and XTO Energy (XTO - Cramer's Take - Stockpickr), which he owns for Action Alerts PLUS, Cramer said.

Furthermore, in the video-game arena, he said he likes Electronic Arts (ERTS - Cramer's Take - Stockpickr) and Activision (ATVI - Cramer's Take - Stockpickr).

"The 1990 playbook hasn't steered us wrong yet," Cramer said. It's time to spend less time worrying about losing money and spend more time looking for opportunities.

Gen-Probe an Exciting Story

If market players want "protection combined with a really long-term trend," the best place to look is diagnostics, Cramer said. "These stocks are the holy grail of defense [and] are the ultimate health care-cost containment names out there."

Gen-Probe (GPRO - Cramer's Take - Stockpickr), which has a fast technology for detecting infectious microorganisms, is a diagnostics company Cramer likes.

Recently, the company's trial of a new HPV test was pushed back a quarter, and its food-testing deal with partner 3M (MMM - Cramer's Take - Stockpickr) fell apart, Cramer said. Consequently, the stock went from $72 to $65.

Cramer brought on Henry Nordhoff, the CEO of Gen-Probe, to explain what happened with 3M.

"3M is a fantastic company, [but] we just had a difference of opinion," Nordhoff said.

After doing some research, 3M believed that when its and Gen-Probe's profits were added to the cost of making the food-testing product, the price point would be too high, the chief said. However, half the food processors in the business hold inventory while they're waiting for test results, and Nordhoff believes these companies would be willing to pay more to offset the cost of food going bad because of delays.

Further, the HPV test has become a problem only because the Food and Drug Administration keeps changing its rules and trying to come up with a gold standard for HPV testing, Nordhoff said.

These two negatives are why the stock has come down, Cramer said, and they already are priced into Gen-Probe. However, the positives of two tests the company has for prostate cancer are not priced in, he said. Therefore, the stock should go up.

Cramer called Gen-Probe "a very exciting" story that is also safe.

Am I Diversified?

During the "Am I Diversified?" game, Cramer's first caller named the following five stocks: Intuitive Surgical, ValueClick (VCLK - Cramer's Take - Stockpickr), AT&T (T - Cramer's Take - Stockpickr), Saks (SKS - Cramer's Take - Stockpickr) and Hologic (HOLX - Cramer's Take - Stockpickr), a stock Cramer owns for his charitable trust.

Cramer suggested the caller get out of Intuitive Surgical or Hologic and pick up a defensive stock instead.

The second caller asked if he was diversified with these five plays: ING (ING - Cramer's Take - Stockpickr), Google (GOOG - Cramer's Take - Stockpickr), Anheuser-Busch (BUD - Cramer's Take - Stockpickr), Bank of America (BAC - Cramer's Take - Stockpickr) and Sirius Satellite Radio (SIRI - Cramer's Take - Stockpickr).

Cramer said the caller shouldn't have two banks in his portfolio. He advised the caller to sell ING and pick up a defensive play.